Common Good

 

The Common Good

a conversation series hosted by the Pediatric Cancer Data Commons

 

 

 Putting Children First: New Models

for Pediatric Oncology Drug Development

Join Sam Blackman, MD, PhD, for a discussion of how pediatric oncology drug development can change for the better. Dr. Blackman, who has led the early clinical development of more than 10 novel cancer therapeutics, will describe the challenges that have limited the pace of development of new therapeutics for pediatric cancer, new business models that may be capable of changing this dynamic, and how the pediatric oncology ecosystem can work together to enable success.

 

Tuesday, January 25, 2022

11:00am – 12:00pm CST

 

 

 

Sam Blackman

Sam Blackman, co-founder and Chief Medical Officer of Day One Biopharmaceuticals, is a physician-scientist trained in pediatric hematology/oncology and neuro-oncology, and has led the early clinical development of more than 10 novel cancer therapeutics. Prior to founding Day One, Dr. Blackman was Head of Clinical Development at Mavupharma, where he led the advancement of a novel immunotherapeutic towards Phase 1 clinical trials. Prior to Mavupharma he was Head of Clinical Development at Silverback Therapeutics. Prior to Silverback, Dr. Blackman held roles of increasing responsibility at Juno Therapeutics, Seattle Genetics, Merck, and GlaxoSmithKline. Dr. Blackman was responsible for the pediatric development of dabrafenib, resulting in the first industry-sponsored pediatric oncology “basket trial.” Through roles at CureSearch for Children’s Cancer, and ACCELERATE, Dr. Blackman is an active leader in the pediatric oncology drug development community.